---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-010579"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T06:57:23.921090+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "medium"
source: SEC EDGAR
---

# ZIVO CEO letter highlights algae antioxidant validation and animal health progress

## Summary
- Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.
- Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.
- Management and board personally invested in the Company, signaling conviction in undervalued stock.
- Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.
- CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments.

## SEC filing metadata
- accession: 0001654954-25-010579
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/0001654954-25-010579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-010579
- JSON: https://secwatch.observer/filing/0001654954-25-010579.json
- Plain text: https://secwatch.observer/filing/0001654954-25-010579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.